OncoMatch/Clinical Trials/NCT04501718
Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children
Is NCT04501718 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Apatinib Combined With Temozolomide and Etoposide Capsules for recurrent medulloblastoma.
Treatment: Apatinib Combined With Temozolomide and Etoposide Capsules — This study is a prospective single-center clinical study, which aims to observe and evaluate the efficacy and safety of apatinib combined with temozolomide and oral etoposide in the treatment of recurrent medulloblastoma in children.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Prior therapy
Must have received: radiation therapy
The time interval from the last radiotherapy is ≥4 weeks.
Must have received: chemotherapy
The time interval from the last chemotherapy is ≥4 weeks, and the patients have fully recovered from the acute toxicity of the last treatment. If you receive nitrosourea chemotherapeutics before enrollment, the interval between enrollment and the last chemotherapy is ≥6 weeks.
Must have received: surgery
After biopsy or surgery, the first postoperative pathological diagnosis is medulloblastoma.
Cannot have received: anti-tumor angiogenesis drugs
Past application of anti-tumor angiogenesis drugs
Lab requirements
Blood counts
HGB≥100g/L; WBC≥3.0×10^9/L; NEUT≥1.5×10^9/L; PLT ≥100×10^9/L; no blood transfusion within 14 days
Kidney function
Serum Cr≤1.5x ULN or endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula)
Liver function
BIL≤1.5x ULN; ALT and AST≤2.0x ULN
Cardiac function
ECG: heart rate 55-100 bpm, QTc<480ms, T wave normal or low, ST segment normal or non-specific changes
The main organ functions are normal, and there is no serious blood, heart, lung, liver, kidney dysfunction and immune deficiency diseases. The laboratory inspection meets the following requirements: ... (see above for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04501718 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-tumor angiogenesis drugs disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages